Condensed Consolidated Statements of Operations (Unaudited) (USD $) In Thousands, except Per Share data	3 Months Ended		9 Months Ended
	Sep. 30, 2011	Sep. 30, 2010	Sep. 30, 2011	Sep. 30, 2010
Revenue, net:
Core companion animal health	$ 14,263	$ 14,144	$ 44,727	$ 43,667
Other vaccines, pharmaceuticals and products	3,345	3,491	9,833	6,769
Total revenue, net	17,608	17,635	54,560	50,436
Cost of revenue	10,781	11,042	31,966	31,791
Gross profit	6,827	6,593	22,594	18,645
Operating expenses:
Selling and marketing	3,753	3,912	11,283	11,604
Research and development	311	455	1,345	1,300
General and administrative	2,355	1,861	7,131	6,071
Total operating expenses	6,419	6,228	19,759	18,975
Operating income (loss)	408	365	2,835	(330)
Interest and other expense, net	(64)	(118)	101	177
Income (loss) before income taxes	472	483	2,734	(507)
Current tax expense	30	(37)	189	27
Deferred tax expense (benefit)	154	279	884	(280)
Total income tax expense (benefit)	184	242	1,073	(253)
Net income (loss)	$ 288	$ 241	$ 1,661	$ (254)
Basic net income (loss) per share	$ 0.06	$ 0.05	$ 0.32	$ (0.05)
Diluted net income (loss) per share	$ 0.05	$ 0.05	$ 0.31	$ (0.05)
Weighted average outstanding shares used to compute basic net income (loss) per share	5,239	5,224	5,235	5,219
Weighted average outstanding shares used to compute diluted net income (loss) per share	5,411	5,238	5,337	5,219